Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 18482975 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Hou X, et al. (2008) SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem 283, 20015-26 18482975
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S80-p - ACC1 (human)
Orthologous residues
ACC1 (human): S80‑p, ACC1 iso4 (human): S117‑p, ACC1 (mouse): S79‑p, ACC1 iso2 (mouse): S117‑p, ACC1 (rat): S79‑p, ACC1 iso2 (rat): S79‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  liver cancer
 Relevant cell lines - cell types - tissues:  293 (epithelial), HepG2 (hepatic)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
S17834 increase
nicotinamide S17834 inhibit treatment-induced increase
splitomicin S17834 inhibit treatment-induced increase
siRNA S17834 SIRT1 (human) inhibit treatment-induced increase
S17834 SIRT1 (human) inhibit treatment-induced increase inactive
resveratrol increase
splitomicin resveratrol inhibit treatment-induced increase
resveratrol SIRT1 (human) inhibit treatment-induced increase inactive
siRNA SIRT1 (human) decrease
SIRT1 (human) increase

T183-p - AMPKA1 (human)
Orthologous residues
AMPKA1 (human): T183‑p, AMPKA1 (mouse): T183‑p, AMPKA1 (rat): T183‑p, AMPKA1 (fruit fly): T184‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  liver cancer
 Relevant cell lines - cell types - tissues:  293 (epithelial), HepG2 (hepatic)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose decrease
resveratrol glucose inhibit treatment-induced decrease
resveratrol increase
resveratrol inhibit treatment-induced increase splitomicin
resveratrol SIRT1 (human) inhibit treatment-induced increase inactive
S17834 increase
nicotinamide S17834 inhibit treatment-induced increase
S17834 inhibit treatment-induced increase splitomicin
siRNA S17834 SIRT1 (human) inhibit treatment-induced increase
S17834 SIRT1 (human) inhibit treatment-induced increase inactive
siRNA SIRT1 (human) decrease
AICAR increase
LKB1 (human) increase
S17834 LKB1 (human) augment treatment-induced increase
resveratrol LKB1 (human) augment treatment-induced increase
SIRT1 (human) LKB1 (human) augment treatment-induced increase
SIRT1 (human) increase

T172-p - AMPKA2 (human)
Orthologous residues
AMPKA2 (human): T172‑p, AMPKA2 (mouse): T172‑p, AMPKA2 (rat): T172‑p, AMPKA2 (pig): T172‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  liver cancer
 Relevant cell lines - cell types - tissues:  293 (epithelial), HepG2 (hepatic)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose decrease
resveratrol glucose inhibit treatment-induced decrease
resveratrol increase
resveratrol inhibit treatment-induced increase splitomicin
resveratrol SIRT1 (human) inhibit treatment-induced increase inactive
S17834 increase
nicotinamide S17834 inhibit treatment-induced increase
S17834 inhibit treatment-induced increase splitomicin
siRNA S17834 SIRT1 (human) inhibit treatment-induced increase
S17834 SIRT1 (human) inhibit treatment-induced increase inactive
siRNA SIRT1 (human) decrease
AICAR increase
LKB1 (human) increase
S17834 LKB1 (human) augment treatment-induced increase
resveratrol LKB1 (human) augment treatment-induced increase
SIRT1 (human) LKB1 (human) augment treatment-induced increase
SIRT1 (human) increase

S428-p - LKB1 (human)
Orthologous residues
LKB1 (human): S428‑p, LKB1 iso2 (human): , LKB1 (mouse): S431‑p, LKB1 (rat): S431‑p, LKB1 (pig): S339‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  liver cancer
 Relevant cell lines - cell types - tissues:  293 (epithelial), HepG2 (hepatic)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AICAR increase small increase
S17834 increase
resveratrol increase

S79-p - ACC1 (mouse)
Orthologous residues
ACC1 (human): S80‑p, ACC1 iso4 (human): S117‑p, ACC1 (mouse): S79‑p, ACC1 iso2 (mouse): S117‑p, ACC1 (rat): S79‑p, ACC1 iso2 (rat): S79‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  liver
 Cellular systems studied:  tissue
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SIRT1 (human) increase

T183-p - AMPKA1 (mouse)
Orthologous residues
AMPKA1 (human): T183‑p, AMPKA1 (mouse): T183‑p, AMPKA1 (rat): T183‑p, AMPKA1 (fruit fly): T184‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  liver
 Cellular systems studied:  tissue
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SIRT1 (human) increase

T172-p - AMPKA2 (mouse)
Orthologous residues
AMPKA2 (human): T172‑p, AMPKA2 (mouse): T172‑p, AMPKA2 (rat): T172‑p, AMPKA2 (pig): T172‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  liver
 Cellular systems studied:  tissue
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SIRT1 (human) increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.